Induction of specific immune responses by polycation-based vaccines

Journal of Immunology

Volumn 169, Issue 9, 2002, Pages 5217-5226

  Lührs, Petra ^a   Schmidt, Walter ^a   Kutil, Raphaela ^a   Buschle, Michael ^a   Wagner, Stephan N ^a   Stingl, Georg ^a   Schneeberger, Achim ^a  

^a Universitatsklinik fur Dermatologie   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BETA GALACTOSIDASE; CD4 ANTIGEN; CD8 ANTIGEN; POLYARGININE; POLYCATION;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER; CANCER IMMUNOTHERAPY; CANCER MODEL; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG POTENTIATION; HUMORAL IMMUNITY; IMMUNOGENICITY; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR IMMUNITY; VACCINATION;

EID: 0036838692     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.169.9.5217     Document Type: Article

References (52)

1. Fearon, E. R., D. M. Pardoll, T. Itaya, P. Golumbek, H. I. Levitsky, J. W. Simons, H. Karasuyama, B. Vogelstein, and P. Frost. 1990. Interleukin-2 production by tumor cells bypasses T helper function in the generation of an antitumor response. Cell 60:397.
2. Dranoff, G., E. Jaffee, A. Lazenby, P. Golumbek, H. Levitsky, K. Brose, V. Jackson, H. Hamada, D. Pardoll, and R. C. Mulligan. 1993. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl. Acad. Sci. USA 90:3539.
3. Schneeberger, A., M. Goos, G. Stingl, and S. N. Wagner. 2000. Management of malignant melanoma: New developments in immune and gene therapy. Clin. Exp. Dermatol. 25:509.
4. Zatloukal, K., A. Schneeberger, M. Berger, W. Schmidt, F. Koszik, R. Kutil, M. Cotten, E. Wagner, M. Buschle, G. Maass, et al. 1995. Elicitation of a systemic and protective anti-melanoma immune response by an IL-2-based vaccine: Assessment of critical cellular and molecular parameters. J. Immunol. 154:3406.
5. Schreiber, S., E. Kämpgen, E. Wagner, D. Pirkhammer, J. Trcka, H. Korschan, A. Lindemann, R. Dorffner, H. Kittler, F. Kasteliz, et al. 1999. Immunotherapy of metastatic malignant melanoma by a vaccine consisting of autologous interleukin 2-transfected cancer cells: Outcome of a phase I study. Hum. Gene Ther. 10:983.
6. Boon, T., and P. van der Bruggen. 1996. Human tumor antigens recognized by T lymphocytes. J. Exp. Med. 183:725.
7. Pardoll, D. M. 1998. Cancer vaccines. Nat. Med. 4:525.
8. Condon, C., S. C. Watkins, C. M. Celluzzi, K. Thompson, and L. D. Falo, Jr. 1996. DNA-based immunization by in vivo transfection of dendritic cells. Nat. Med. 2:1122.
9. + T cells after gene gun immunization. J. Exp. Med. 188:1075.
10. Wagner, S. N., C. Wagner, P. Lührs, T. K. Weimann, R. Kutil, M. Goos, G. Stingl, and A. Schneeberger. 2000. Intracutaneous genetic immunization with autologous melanoma-associated antigen Pmel17/gp100 induces T cell-mediated tumor protection in vivo. J. Invest. Dermatol. 115:1082.
11. Bronte, V., K. Tsung, J. B. Rao, P. W. Chen, M. Wang, S. A. Rosenberg, and N. P. Restifo. 1995. IL-2 enhances the function of recombinant poxvirus-based vaccines in the treatment of established pulmonary metastases. J. Immunol. 154:5282.
12. Rosenberg, S. A., Y. Zhai, J. C. Yang, D. J. Schwartzentruber, P. Hwu, F. M. Marincola, S. L. Topalian, N. P. Restifo, C. A. Seipp, J. H. Einhorn, et al. 1998. Immunizing patients with metastatic melanoma using recombinant adeno-viruses encoding MART-1 or gp100 melanoma antigens. J. Natl. Cancer Inst. 90:1894.
13. Pan, Z. K., G. Ikonomidis, A. Lazenby, D. Pardoll, and Y. Paterson. 1995. A recombinant Listeria monocytogenes vaccine expressing a model tumour antigen protects mice against lethal tumour cell challenge and causes regression of established tumours. Nat. Med. 1:471.
14. Mayordomo, J. I., T. Zorina, W. J. Storkus, L. Zitvogel, C. Celluzzi, L. D. Falo, C. J. Melief, S. T. Ildstad, W. M. Kast, A. B. DeLeo, and M. T. Lotze. 1995. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1:1297.
15. Ossevoort, M. A., M. C. Feltkamp, K. J. van Veen, C. J. Melief, and W. M. Kast. 1995. Dendritic cells as carriers for a cytotoxic T-lymphocyte epitope-based peptide vaccine in protection against a human papillomavirus type 16-induced tumor. J. Immunother. Emphasis. Tumor Immunol. 18:86.
16. Celluzzi, C. M., J. I. Mayordomo, W. J. Storkus, M. T. Lotze, and L. D. Falo, Jr. 1996. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med. 183:283.
17. + progenitor-derived dendritic cell vaccine. Cancer Res. 61:6451.
18. Thumer, B., I., Haendle, C. Roder, D. Dieckmann, P. Keikavoussi, H. Jonuleit, A. Bender, C. Maczek, D. Schreiner, D. P. von Den, et al. 1999. Vaccination with MAGE-3.A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190:1669.
19. Paglia, P., C. Chiodoni, M. Rodolfo, and M. P. Colombo. 1996. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183:317.
20. Zöller, M., and O. Christ. 2001. Prophylactic tumor vaccination: Comparison of effector mechanisms initiated by protein versus DNA vaccination. J. Immunol. 166:3440.
21. Boczkowski, D., S. K. Nair, D. Snyder, and E. Gilboa. 1996. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184:465.
22. Schmidt, W., P. Steinlein, M. Buschle, T. Schweighoffer, E. Herbst, K. Mechtler, H. Kirlappos, and M. L. Bimstiel. 1996. Transloading of tumor cells with foreign major histocompatibility complex class I peptide ligand: A novel general strategy for the generation of potent cancer vaccines. Proc. Natl. Acad. Sci. USA 93:9759.
23. Buschle, M., W. Schmidt, W. Zauner, K. Mechtler, B. Trska, H. Kirlappos, and M. L. Birnstiel. 1997. Transloading of tumor antigen-derived peptides into antigen-presenting cells. Proc. Natl. Acad. Sci. USA 94:3256.
24. Schmidt, W., M. Buschle, W. Zauner, H. Kirlappos, K. Mechtler, B. Trska, and M. L. Bimstiel. 1997. Cell-free tumor antigen peptide-based cancer vaccines. Proc. Natl. Acad. Sci. USA 94:3262.
25. Zauner, W., K. Lingnau, F. Mattner, A. von Gabain, and M. Buschle. 2001. Defined synthetic vaccines. J. Biol. Chem. 382:581.
26. Rammensee, H. G., T. Friede, and S. Stevanoviic. 1995. MHC ligands and peptide motifs: First listing. Immunogenetics 41:178.
27. Hartikka, J., M. Sawdey, F. Cornefert-Jensen, M. Margalith, K. Barnhart, M. Nolasco, H. L. Vahlsing, J. Meek, M. Marquet, P. Hobart, et al. 1996. An improved plasmid DNA expression vector for direct injection into skeletal muscle. Hum. Gene Ther. 7:1205.
28. Kocikova, A., A. Kolesaric, F. Koszik, G. Stingl, and A. Elbe-Bürger. 1998. Murine Langerhans cells cultured under serum-free conditions mature into potent stimulators of primary immune responses in vitro and in vivo. J. Immunol. 161:4033.
29. + T cells. Eur. J. Immunol. 24:343.
30. Speidel, K., W. Osen, S. Faath, I. Hilgert, R. Obst, J. Braspenning, F. Momburg, G. J. Hammerling, and H. G. Rammensee. 1997. Priming of cytotoxic T lymphocytes by five heat-aggregated antigens in vivo: Conditions, efficiency, and relation to antibody responses. Eur. J. Immunol. 27:2391.
31. + T cells using an ELISPOT assay. J. Immunol. Methods 181:45.
32. Maurer, D., C. Ebner, B. Reininger, E. Fiebiger, D. Kraft, J. P. Kinet, and G. Stingl. 1995. The high affinity IgE receptor (FcεRI) mediates IgE-dependent allergen presentation. J. Immunol. 154:6285.
33. Bullock, T. N., T. A. Colella, and V. H. Engelhard. 2000. The density of peptides displayed by dendritic cells affects immune responses to human tyrosinase and gp100 in HLA-A2 transgenic mice. J. Immunol. 164:2354.
34. Bevan, M. J. 1976. Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay. J. Exp. Med. 143:1283.
35. Pfeifer, J. D., M. J. Wick, R. L. Roberts, K. Findlay, S. J. Normark, and C. V. Harding. 1993. Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature 361:359.
36. Harding, C. V., and R. Song. 1994. Phagocytic processing of exogenous particulate antigens by macrophages for presentation by class I MHC molecules. J. Immunol. 153:4925.
37. Kovacsovics-Bankowski, M., and K. L. Rock. 1995. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science 267:243.
38. Kovacsovics-Bankowski, M., K. Clark, B. Benacerraf, and K. L. Rock. 1993. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc. Natl. Acad. Sci. USA 90:4942.
39. Rodriguez, A., A. Regnault, M. Kleijmeer, P. Ricciardi-Castagnoli, and S. Amigorena. 1999. Selective transport of internalized antigens to the cytosol for MHC class I presentation in dendritic cells. Nat. Cell Biol. 1:362.
40. Kurts, C., J. F. Miller, R. M. Subramaniam, F. R. Carbone, and W. R. Heath. 1998. Major histocompatibility complex class I-restricted cross-presentation is biased towards high dose antigens and those released during cellular destruction. J. Exp. Med. 188:409.
41. Heath, W. R., and F. R. Carbone. 2001. Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. 19:47.
42. Schwarze, S. R., A. Ho, A. Vocero-Akbani, and S. F. Dowdy. 1999. In vivo protein transduction: Delivery of a biologically active protein into the mouse. Science 285:1569.
43. Mitchell, D. J., D. T. Kim, L. Steinman, C. G. Fathman, and J. B. Rothbard. 2000. Polyarginine enters cells more efficiently than other polycationic homopolymers. J. Pept. Res. 56:318.
44. Wender, P. A., D. J. Mitchell, K. Pattabiraman, E. T. Pelkey, L. Steinman, and J. B. Rothbard. 2000. The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: Peptoid molecular transporters. Proc. Natl. Acad. Sci. USA 97:13003.
45. Schneeberger, A., F. Koszik, and G. Stingl. 1995. Immunologic host defense in melanoma: Delineation of effector mechanisms involved and of strategies for the augmentation of their efficacy. J. Invest. Dermatol. 105:110.S.
46. + T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med. 192:1213.
47. Dhodapkar, M. V., R. M. Steinman, J. Krasovsky, C. Munz, and N. Bhardwaj. 2001. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193:233.
48. Roncarolo, M. G., M. K. Levings, and C. Traversari. 2001. Differentiation of T regulatory cells by immature dendritic cells. J. Exp. Med. 193:F5.
49. Chiodoni, C., P. Paglia, A. Stoppacciaro, M. Rodolfo, M. Parenza, and M. P. Colombo. 1999. Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response. J. Exp. Med. 190:125.
50. Mattner, F., J. K. Fleitmann, K. Lingnau, W. Schmidt, A. Egyed, J. Fritz, W. Zauner, B. Wittmann, I. Gorny, M. Berger, et al. 2002. Vaccination with poly-L-arginine as immunostimulant for peptide vaccines: INduction of potent and long-lasting T-cell responses against cancer antigens. Cancer Res. 62:1477.
51. Ludewig, B., F. Barchiesi, M. Pericin, R. M. Zinkernagel, H. Hengartner, and R. A. Schwendener. 2000. In vivo antigen loading and activation of dendritic cells via a liposomal peptide vaccine mediates protective antiviral and antitumour immunity. Vaccine 19:23.
52. Pior, J., T. Vogl, C. Sorg, and E. Macher. 1999. Free hapten molecules are dispersed by way of the bloodstream during contact sensitization to fluorescein isothiocyanate. J. Invest. Dermatol. 113:888.